Pui, Ching-Hon <br/><br/>
Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.  [electronic resource] 

 -  The Lancet. Oncology  Apr 2015 
 - 465-74 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(15)70082-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Asparaginase--administration & dosage<br/>Child<br/>Child, Preschool<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Infant<br/>Male<br/>Methotrexate--administration & dosage<br/>Neoplasm Recurrence, Local--drug therapy<br/>Neoplasm, Residual--chemically induced<br/>Precursor Cell Lymphoblastic Leukemia-Lymphoma--drug therapy<br/>Prednisone--administration & dosage<br/>Prospective Studies<br/>Remission Induction<br/>Risk Factors<br/>United States<br/>Vincristine--administration & dosage